Total Impact of Cannabis Market Projected to Reach $48 Billion in 2019

The cannabis markets are growing like a weed in both the U.S. and global markets. Each projection seems to raise the ceiling even higher than before. A recent article in the Marijuana Business Daily projected that: “Total economic impact of the cannabis industry will range from $39.2 billion to $48 billion in 2019 – about a 35% increase over 2018 and the U.S. cannabis sales in 2018 were between $8.6 billion and $10.8 billion – more than U.S. spending on e-cigarettes, the video game Fortnite and Goldfish crackers and U.S. sales of cannabis in 2019 will be about 35% higher than 2018 and could reach $30 billion by 2023. But are not just the industry giants that have green fields in front of them. Local dispensaries and recreational shops are a big part of the revenue tsunami. Another industry website laid forth the following industry picture and accompanying statistics: “As more states approve cannabis for use, an entirely new market has cropped up in the United States. Medical dispensaries, as well as recreational shops, are opening to supply marijuana to a broad base of consumers.” Active Companies from around the market with current developments this week include: Marijuana Company of America, Inc. (OTCQB: MCOA), Hemp Inc. (OTCPK: HEMP), Medical Marijuana, Inc. (OTCPK: MJNA), Sipp Industries, Inc. (OTCPK: SIPC), Smart Cannabis Corp. (OTCPK: SCNA).

Medical Marijuana, Inc. Subsidiary Kannaway® Grows International Leadership Team With Janne Heimonen as Managing Director of European Division

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that that its subsidiary Kannaway® has appointed Janne Heimonen as Managing Director of its burgeoning European Division.
Stock Symbols

Medical Marijuana, Inc. Subsidiary Kannaway® Announces Updated Branding Strategy and Website to Expand Consumer Reach

Medical Marijuana, Inc. (OTC: MJNA) (“the Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that its subsidiary Kannaway® has launched a completely redesigned website and the rebranding of its globally recognized hemp-derived cannabidiol (CBD) products.
Stock Symbols

Medical Marijuana, Inc. and Subsidiaries Kannaway® and HempMeds® Announce June 2019 as the Largest Sales Bookings Month in Company History

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the company and its subsidiaries Kannaway® and HempMeds® had their largest-ever (unaudited) sales bookings month in the Company’s history in June 2019. The Company also reached major milestones in its business operations.
Stock Symbols

Medical Marijuana, Inc. Subsidiary Kannaway® Announces European Industrial Hemp Association Membership

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has become a member of the European Industrial Hemp Association (EIHA) and will participate in the organization’s operational and legislative activities.
Stock Symbols

Increased Customer Acceptance and Governmental Deregulation Fueling Huge Cannabis Revenue Opportunities

As more jurisdictions have approved medicinal uses of cannabis, many of them have followed with approval of consumer recreational uses… and more food & other consumer CBD infused products are increasingly on the rise as well. This formula should continue the rise in both the projections and in the cannabis markets overall revenues for years to come. A report from Mordor Intelligence, forecasts that: “The cannabis market was valued at USD 14.5 billion in 2018, and it is projected to reach 89.1 billion by 2024, with a CAGR of 37% during the forecast period. The drivers identified in the market are medicinal properties of cannabis, increasing legalization of cannabis, and increasing advances in genetic development and intellectual property of cannabis. Medicinal cannabis accounts for the majority share of the cannabis market, when segmented on the basis of usage. Many countries have legalized the usage of cannabis for medicinal purposes. Many countries, where cannabis has been legalized, have a large adult population aged 50 and above. This increases the demand for medicinal cannabis, as the affinity of getting sick with chronic diseases increases after 50 years. “The growth rate can be attributed to the fact that various countries are now legalizing the usage of cannabis for medical purposes and various states in the US are legalizing the usage of cannabis for recreational purposes as well. North America accounts for more than 95% of the cannabis market, with the US alone making up more than 90% share of the North American market. In the cannabis market, companies are very active and are constantly involved in acquiring shares and developing new products to attract a larger portion of consumers toward their products. Active Companies from around the market with current developments this week include: Marijuana Company of America, Inc. (OTCQB:MCOA), Medical Marijuana, Inc. (OTCPK: MJNA), Kona Gold Solutions, Inc. (OTCPK: KGKG), HEXO Corp. (NYSE: HEXO) (TSX: HEXO), Terra Tech Corp. (OTCQX: TRTC).

Medical Marijuana, Inc. Issues Letter to Shareholders

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that it has issued a letter to its shareholders, providing commentary on the Company’s recent financial and operational results and upcoming objectives.
Stock Symbols

Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies, Inc.’s Cannabinoid Oral Care Products Registered For Use In Clinical Trials Through Australian Healthcare Partner

Medical Marijuana, Inc. (OTC:MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that products from the Company’s major investment company AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM”), a world leader in cannabinoid research and development, were included in registration for clinical trials through the Australian and New Zealand Clinical Trial Registry. The products will be used during the trial are part of AXIM’s patented oral care line and include its cannabinoid-based mouthwash and toothpaste.

Dixie Botanicals®, Subsidiary of Medical Marijuana, Inc., Announces Partnership with Surface Products Corp. To Sell Fitness-Focused CBD-Infused Sunscreen

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Dixie Botanicals® has partnered with Surface Products Corp. to sell a fitness-focused hemp-derived CBD sunscreen for active consumers.
Stock Symbols